-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Laruparetigene Zovaparvovec in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Laruparetigene Zovaparvovec in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Laruparetigene Zovaparvovec in Retinitis Pigmentosa (Retinitis) Drug Details: Laruparetigene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BDB-201 in Metastatic Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDB-201 in Metastatic Liver Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDB-201 in Metastatic Liver Cancer Drug Details: Orien X-010 (BDB-201)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Metastatic Melanoma Drug Details: Vorolanib (Fumena) is an indoline...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Non-Small Cell Lung Cancer Drug Details: Vorolanib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Thymic Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Thymic Carcinoma Drug Details: Vorolanib (Fumena) is an indoline...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ensartinib Hydrochloride in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ensartinib Hydrochloride in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ensartinib Hydrochloride in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ganaxolone in Status Epilepticus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ganaxolone in Status Epilepticus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ganaxolone in Status Epilepticus Drug Details: Ganaxolone (Ztalmy) is a synthetic...
-
Product Insights
New5-Hydroxytryptamine Receptor 2A – Drugs In Development, 2024
The 5-Hydroxytryptamine Receptor 2A pipeline drugs market research report outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Metabolic Disorders, Immunology, and Genetic Disorders which include indications of Schizophrenia, Unspecified Psychiatric Disorders, Obesity, Metabolic Disorders, Inflammation, Psoriasis, Fragile X Syndrome, and Prader-Willi Syndrome (PWS). It also reviews...
-
Product Insights
NewMuscarinic Acetylcholine Receptor M4 – Drugs In Development, 2024
The Muscarinic Acetylcholine Receptor M4 pipeline drugs market research report outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Genetic Disorders, Undisclosed, and Cardiovascular which include indications of Schizophrenia, Alzheimer's Disease, Fragile X Syndrome, Tuberous Sclerosis, Unspecified Rare Disease, and Systolic Hypertension. It also reviews key...
-
Product Insights
NewMetabotropic Glutamate Receptor 5 – Drugs In Development, 2024
The Metabotropic Glutamate Receptor 5 pipeline drugs market research report outlays comprehensive information on the Metabotropic Glutamate Receptor 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Genetic Disorders, Ophthalmology, and Cardiovascular which include indications of Anxiety Disorders, Depression, Fragile X Syndrome, Tuberous Sclerosis, Blepharospasm, and Stroke. It also reviews key players involved in...